340 related articles for article (PubMed ID: 32057199)
1. [Current questions of multiple sclerosis: the secunder progressive form of the disease].
Vécsei L
Ideggyogy Sz; 2020 Jan; 73(1-2):7-14. PubMed ID: 32057199
[TBL] [Abstract][Full Text] [Related]
2. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis.
Barro C; Benkert P; Disanto G; Tsagkas C; Amann M; Naegelin Y; Leppert D; Gobbi C; Granziera C; Yaldizli Ö; Michalak Z; Wuerfel J; Kappos L; Parmar K; Kuhle J
Brain; 2018 Aug; 141(8):2382-2391. PubMed ID: 29860296
[TBL] [Abstract][Full Text] [Related]
3. 7 T imaging reveals a gradient in spinal cord lesion distribution in multiple sclerosis.
Ouellette R; Treaba CA; Granberg T; Herranz E; Barletta V; Mehndiratta A; De Leener B; Tauhid S; Yousuf F; Dupont SM; Klawiter EC; Sloane JA; Bakshi R; Cohen-Adad J; Mainero C
Brain; 2020 Oct; 143(10):2973-2987. PubMed ID: 32935834
[TBL] [Abstract][Full Text] [Related]
4. Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis.
Brownlee WJ; Altmann DR; Prados F; Miszkiel KA; Eshaghi A; Gandini Wheeler-Kingshott CAM; Barkhof F; Ciccarelli O
Brain; 2019 Aug; 142(8):2276-2287. PubMed ID: 31342055
[TBL] [Abstract][Full Text] [Related]
5. Grey matter involvement by focal cervical spinal cord lesions is associated with progressive multiple sclerosis.
Kearney H; Miszkiel KA; Yiannakas MC; Altmann DR; Ciccarelli O; Miller DH
Mult Scler; 2016 Jun; 22(7):910-20. PubMed ID: 26432854
[TBL] [Abstract][Full Text] [Related]
6. The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history.
Sorensen PS; Sellebjerg F; Hartung HP; Montalban X; Comi G; Tintoré M
Brain; 2020 Sep; 143(9):2637-2652. PubMed ID: 32710096
[TBL] [Abstract][Full Text] [Related]
7. Elevated CSF neurofilament proteins predict brain atrophy: A 15-year follow-up study.
Petzold A; Steenwijk MD; Eikelenboom JM; Wattjes MP; Uitdehaag BM
Mult Scler; 2016 Aug; 22(9):1154-62. PubMed ID: 27207456
[TBL] [Abstract][Full Text] [Related]
8. Relapse May Serve as a Mediator Variable in Longitudinal Outcomes in Multiple Sclerosis.
Stone LA; Cutter GR; Fisher E; Richert N; McCartin J; Ohayon J; Bash C; McFarland H
J Neuroimaging; 2016 May; 26(3):296-302. PubMed ID: 26686343
[TBL] [Abstract][Full Text] [Related]
9. Investigation of magnetization transfer ratio-derived pial and subpial abnormalities in the multiple sclerosis spinal cord.
Kearney H; Yiannakas MC; Samson RS; Wheeler-Kingshott CA; Ciccarelli O; Miller DH
Brain; 2014 Sep; 137(Pt 9):2456-68. PubMed ID: 24966048
[TBL] [Abstract][Full Text] [Related]
10. Atrophied Brain Lesion Volume: A New Imaging Biomarker in Multiple Sclerosis.
Dwyer MG; Bergsland N; Ramasamy DP; Jakimovski D; Weinstock-Guttman B; Zivadinov R
J Neuroimaging; 2018 Sep; 28(5):490-495. PubMed ID: 29856910
[TBL] [Abstract][Full Text] [Related]
11. Elevated plasma fibrinogen levels in multiple sclerosis patients during relapse.
Miranda Acuña J; Hidalgo de la Cruz M; Ros AL; Tapia SP; Martínez Ginés ML; de Andrés Frutos CD
Mult Scler Relat Disord; 2017 Nov; 18():157-160. PubMed ID: 29141800
[TBL] [Abstract][Full Text] [Related]
12. [A current view on the MRI diagnosis of multiple sclerosis: an update of 2016 revised MRI criteria].
Bryukhov VV; Krotenkova IA; Morozova SN; Krotenkova MV
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(2. Vyp. 2):66-73. PubMed ID: 28617364
[TBL] [Abstract][Full Text] [Related]
13. [Controversies in neurology: Diagnosis, follow up and therapy of multiple sclerosis with pathomechanismal approach].
Vécsei L
Ideggyogy Sz; 2021 Jul; 74(7-08):249-255. PubMed ID: 34370413
[TBL] [Abstract][Full Text] [Related]
14. Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms.
Nijeholt GJ; van Walderveen MA; Castelijns JA; van Waesberghe JH; Polman C; Scheltens P; Rosier PF; Jongen PJ; Barkhof F
Brain; 1998 Apr; 121 ( Pt 4)():687-97. PubMed ID: 9577394
[TBL] [Abstract][Full Text] [Related]
15. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
16. Predicting cognitive decline in multiple sclerosis: a 5-year follow-up study.
Eijlers AJC; van Geest Q; Dekker I; Steenwijk MD; Meijer KA; Hulst HE; Barkhof F; Uitdehaag BMJ; Schoonheim MM; Geurts JJG
Brain; 2018 Sep; 141(9):2605-2618. PubMed ID: 30169585
[TBL] [Abstract][Full Text] [Related]
17. Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study.
Gold R; Piani-Meier D; Kappos L; Bar-Or A; Vermersch P; Giovannoni G; Fox RJ; Arnold DL; Benedict RHB; Penner IK; Rouyrre N; Kilaru A; Karlsson G; Ritter S; Dahlke F; Hach T; Cree BAC
J Neurol; 2022 Sep; 269(9):5093-5104. PubMed ID: 35639197
[TBL] [Abstract][Full Text] [Related]
18. Intrathecal IgM index correlates with a severe disease course in multiple sclerosis: Clinical and MRI results.
Ozakbas S; Cinar BP; Özcelik P; Baser H; Kosehasanoğullari G
Clin Neurol Neurosurg; 2017 Sep; 160():27-29. PubMed ID: 28622533
[TBL] [Abstract][Full Text] [Related]
19. The role of magnetic resonance techniques in understanding and managing multiple sclerosis.
Miller DH; Grossman RI; Reingold SC; McFarland HF
Brain; 1998 Jan; 121 ( Pt 1)():3-24. PubMed ID: 9549485
[TBL] [Abstract][Full Text] [Related]
20. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability.
Scalfari A; Neuhaus A; Degenhardt A; Rice GP; Muraro PA; Daumer M; Ebers GC
Brain; 2010 Jul; 133(Pt 7):1914-29. PubMed ID: 20534650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
